-
1 month ago | 
nature.com | Avantika Gupta |Fresia Pareja |David Brown |Yingjie Zhu |Juan Blanco-Heredia |Bojana Stefanovska | +11 more
AbstractAcquired genetic alterations drive resistance to endocrine and targeted therapies in metastatic breast cancer; however, the underlying processes engendering these alterations are largely uncharacterized. To identify the underlying mutational processes, we utilized a clinically annotated cohort of 3,880 patient samples with tumor-normal sequencing.
-
Jan 16, 2025 | 
reference.medscape.com | Giuseppe Curigliano
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. The World Health Organization (WHO) released updated brain tumor classification guidelines in 2021, which built upon the traditional histologic classification system that has defined brain tumor staging.
-
Jan 16, 2025 | 
reference.medscape.com | Giuseppe Curigliano
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Isocitrate dehydrogenase (IDH) is an important biomarker in brain cancer and an essential diagnostic criterion in the current World Health Organization (WHO) tumor classification system.
-
Dec 5, 2024 | 01771-4/abstract&sz=64)
ejcancer.com | Giuseppe Curigliano
Keywordsendocrine therapymetastatic breast canceroligoprogressionstereotactic radiotherapyGet full text accessLog in, subscribe or purchase for full access. References1. Siegel, R.L. ∙ Giaquinto, A.N. ∙ Jemal, A. Cancer statistics, 2024CA Cancer J Clin. 2024; 74:12-492. Gennari, A. ∙ André, F. ∙ Barrios, C.H. ... ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology. 2021; 32:1475-14953. Valenza, C. ∙ Trapani, D. ∙ Bidard, F.-C.
-
Jul 18, 2024 | 
onclive.com | Giuseppe Curigliano
CommentaryVideoJuly 18, 2024Author(s):Giuseppe Curigliano, MD, PhD, discusses the implications of treatment with T-DXd in HR+, HER2-low or HER2-ultralow metastatic breast cancer.
-
Jul 15, 2024 | 
onclive.com | Giuseppe Curigliano
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
-
Jun 19, 2024 | 
onclive.com | Giuseppe Curigliano
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology, discusses key findings from the phase 3 DESTINY-Breast06 trial (NCT04494425) investigating fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer who have received prior endocrine therapy.
-
Apr 15, 2024 | 
nature.com | Qingchun Jin |Ann H. Partridge |Brittany L. Bychkovsky |Giuseppe Curigliano |Nabihah Tayob |Sara M. Tolaney
AbstractFollowing the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated.
-
Mar 14, 2024 | 
jamanetwork.com | Dario Trapani |Giuseppe Curigliano
The advent of antibody drug conjugates (ADCs) in cancer treatment raises fundamental questions, such as: does cancer antigen expression influence ADC efficacy? Precision in oncology with targeted agents has been commonly pursued through a perfect match of drugs and their targets. Yet, ADCs have inconstantly been developed based on this paradigm.
-
Dec 19, 2023 | 
nature.com | Giuseppe Curigliano
Recent results from the phase III PHILA trial demonstrate a benefit in terms of progression-free survival derived from the addition of pyrotinib to first-line chemotherapy plus trastuzumab in patients with metastatic HER2-positive breast cancer. Dual HER2 blockade with pyrotinib and trastuzumab is an effective therapeutic strategy but might increase the risk of gastrointestinal toxicity; therefore, the risk-to-benefit ratio should be carefully evaluated. Refers to Ma, F. et al.
